Platelets Indices and Its Role to Predict Liver Fibrosis in Patients With Chronic Hepatitis B Infection
1 other identifier
observational
75
1 country
1
Brief Summary
Platelets indices and its role to predict liver Fibrosis in patients with chronic hepatitis B infection
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Oct 2022
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 2, 2022
CompletedFirst Posted
Study publicly available on registry
October 5, 2022
CompletedStudy Start
First participant enrolled
October 20, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 15, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
December 15, 2023
CompletedOctober 5, 2022
October 1, 2022
10 months
October 2, 2022
October 2, 2022
Conditions
Outcome Measures
Primary Outcomes (1)
Platelets indices and its role to predict liver Fibrosis in patients with chronic hepatitis B infection
Correlation between platelets count and degree of liver Fibrosis in patients with chronic hepatitis B virus through liver fibroscan
Two years
Study Arms (1)
75
patients with chronic hepatitis B infection will be collected and underwill liver fibroscan then corelate between platelets indicies and predict degree of liver fibrosis
Interventions
Patients with CHB virus will do liver fibroscan and correlat between platelets count and degree of liver fibrosis
Eligibility Criteria
patients at Age from 18 to 70 years with chronic hepatits B infection will do liver fibroscan and correlate between platelets indicies and degree of liver fibrosis \-
You may qualify if:
- Age from 18 to 70 years
- without a history of clinical illness
You may not qualify if:
- with other hepatitis virus infection; (b) with alcoholic liver disease; (c) with any disease related to fibrosis (such as connective tissue diseases, chronic obstructive pulmonary disease, kidney failure, tumors, and so on); (d) have received any anti-fibrosis therapy; and (e) pregnancy
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
AssiutU
Asyut, Egypt
Related Publications (2)
Zhong LK, Zhang G, Luo SY, Yin W, Song HY. The value of platelet count in evaluating the degree of liver fibrosis in patients with chronic hepatitis B. J Clin Lab Anal. 2020 Jul;34(7):e23270. doi: 10.1002/jcla.23270. Epub 2020 May 4.
PMID: 32363594BACKGROUNDTan YW, Zhou XB, Ye Y, He C, Ge GH. Diagnostic value of FIB-4, aspartate aminotransferase-to-platelet ratio index and liver stiffness measurement in hepatitis B virus-infected patients with persistently normal alanine aminotransferase. World J Gastroenterol. 2017 Aug 21;23(31):5746-5754. doi: 10.3748/wjg.v23.i31.5746.
PMID: 28883700BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Ahmed AB Maghraby, Professor
Assiut University
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Platelets indices and its role to predict liver Fibrosis in patients with chronic hepatitis B infection
Study Record Dates
First Submitted
October 2, 2022
First Posted
October 5, 2022
Study Start
October 20, 2022
Primary Completion
August 15, 2023
Study Completion
December 15, 2023
Last Updated
October 5, 2022
Record last verified: 2022-10
Data Sharing
- IPD Sharing
- Will not share
the value of platelets count in evaluating the degree of liver fibrosis in patients with chronic hepatits B infecion